(HealthDay News) — There is no evidence of cardiac events or deaths occurring in treatment-compliant genotype-positive long QT syndrome (LQTS) pediatric patients who participate in sports, according to research published in the March 1 issue of JACC: Clinical Electrophysiology.

Peter F. Aziz, MD, from the Cleveland Clinic Lerner College of Medicine, and colleagues conducted a retrospective review on genotype-positive patients referred for the evaluation and management of LQTS between 1998–2013. Two hundred twelve genotype-positive LQTS pediatric patients were included, of whom 103 participated in sports (average follow-up, 7.1 years).

The researchers identified 105 LQTS-disease-causing mutations (58% KCNQ1, 35% KCNH2, 6% SCN5A, 1% KCNE1, and 2% KCNE2). All patients were treated with beta-blockade; one patient was intolerant and one patient noncompliant. Twenty-six and 77 patients participated in competitive sports and recreational sports, respectively. During sports participation, no patients had LTQS symptoms. In two patients, five appropriate implantable cardioverter-defibrillator shocks occurred, although none were related to sports participation.

“In this series no cardiac events and no deaths were observed in treatment-compliant LQTS children while participating in sports in 755 patient-years of follow-up,” the authors write.

One author disclosed financial ties to Medtronic.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)